COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,687 Articles (22,913 medRxiv, 8,774 bioRxiv)

Most recent first Previous |  Page 1966: Articles 19651-19660  | Next

Hospitalization as reliable indicator of second wave COVID-19 pandemic in eight European countries
Allieta, M., Rossi Sebastiano, D.
10.1101/2020.12.31.20249084 — Posted: 2021-01-05
Syncope and COVID-19 disease - a systematic review.
Falcao de Freitas, R., Torres, S. C., Nunes, J. P. L.
10.1101/2020.12.30.20249060 — Posted: 2021-01-05
The impact of COVID-19 vaccination campaigns accounting for antibody-dependent enhancement
Adil M. Y., N., Tsoungui Obama, H. C. J., Ngucho Yvan Mbeutchou, J., Kwamou Ngaha, S. F., Kayanula, L., Kamanga, G., Ibrahim, T. B., Bwanu Iliya, P., Iyanda, S. B., Alawam Nemer, L. H. M., Helle, K. B., Teboh-Ewungkem, M. I., Schneider, K. A.
10.1101/2021.01.04.425198 — Posted: 2021-01-04 Discussion: Onsite
TMPRSS2 structure-phylogeny repositions Avoralstat for SARS-CoV-2 prophylaxis in mice
Sun, Y. J., Velez, G., Parsons, D., Li, K., Ortiz, M., Sharma, S., McCray, P. B., Bassuk, A. G., Mahajan, V. B.
10.1101/2021.01.04.425289 — Posted: 2021-01-04
The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children
Hachim, A., Gu, H., Kavian, O., Kwan, M. Y., Chan, W.-h., Yau, Y. S., Chiu, S. S., Tsang, O. T., Hui, D. S., Ma, F., Lau, E. H., Cheng, S. M., Poon, L. L., Peiris, M. J., Kavian, N., Valkenburg, S. A.
10.1101/2021.01.03.21249180 — Posted: 2021-01-04
SARS-CoV-2 Fusion Peptide has a Greater Membrane Perturbating Effect than SARS-CoV with Highly Specific Dependence on Ca2+
Lai, A. L., Freed, J. H.
10.1101/2021.01.04.425297 — Posted: 2021-01-04
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H., Starr, T. N., Malone, K. D., Chu, H. Y., Bloom, J. D.
10.1101/2020.12.31.425021 — Posted: 2021-01-04 Discussion: Onsite
Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
Mannar, D., Leopold, K., Subramaniam, S.
10.1101/2021.01.03.425141 — Posted: 2021-01-04
The ancient cardioprotective mechanisms of ACE2 bestow SARS-CoV-2 with a wide host range
Castiglione, G. M., Zhou, L., Xu, Z., Neiman, Z., Hung, C.-F., Duh, E. J.
10.1101/2021.01.03.425115 — Posted: 2021-01-04
Spike protein disulfide disruption as a potential treatment for SARS-CoV-2
Grishin, A. M., Dolgova, N. V., Harms, S., Pickering, I. J., George, G. N., Falzarano, D., Cygler, M.
10.1101/2021.01.02.425099 — Posted: 2021-01-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).